OTCMKTS:PTKFF - PT Kalbe Farma Tbk. Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.10
+0.30 (1.20%)

This chart shows the closing price for PTKFF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PT Kalbe Farma Tbk. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTKFF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTKFF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for PT Kalbe Farma Tbk. in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.10.

This chart shows the closing price for PTKFF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in PT Kalbe Farma Tbk.. This rating has held steady since January 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/28/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy
6/2/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
PT Kalbe Farma Tbk. logo
PT Kalbe Farma Tbk engages in the development, distribution, and trading of pharmaceutical products. It operates through the following divisions: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescription Pharmaceutical division offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores. The Consumer Health division includes over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals division sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution and Logistic division maintains distribution of the company's and third party principal's products across Indonesia; and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.
Read More

Today's Range

Now: $0.10
Low: $0.10
High: $0.10

50 Day Range

MA: $0.10
Low: $0.10
High: $0.12

52 Week Range

Now: $0.10
Low: $0.09
High: $0.13

Volume

N/A

Average Volume

88,385 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of PT Kalbe Farma Tbk.?

The following Wall Street research analysts have issued reports on PT Kalbe Farma Tbk. in the last year: The Goldman Sachs Group, Inc..
View the latest analyst ratings for PTKFF.

What is the current price target for PT Kalbe Farma Tbk.?

0 Wall Street analysts have set twelve-month price targets for PT Kalbe Farma Tbk. in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for PT Kalbe Farma Tbk. in the next year.
View the latest price targets for PTKFF.

What is the current consensus analyst rating for PT Kalbe Farma Tbk.?

PT Kalbe Farma Tbk. currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTKFF will outperform the market and that investors should add to their positions of PT Kalbe Farma Tbk..
View the latest ratings for PTKFF.

What other companies compete with PT Kalbe Farma Tbk.?

Other companies that are similar to PT Kalbe Farma Tbk. include Organon & Co., JCR Pharmaceuticals, Kyowa Kirin, Orion Oyj and Santen Pharmaceutical.

How do I contact PT Kalbe Farma Tbk.'s investor relations team?

PT Kalbe Farma Tbk.'s physical mailing address is Gedung KALBE, Jakarta, Jakarta Raya. The company's listed phone number is 622142873888. The official website for PT Kalbe Farma Tbk. is www.kalbe.co.id.